The Asia Pacific Spinal Muscular Atrophy Treatment Market should witness market growth of 19.4% CAGR during the forecast period (2022-2028).
Survival motor neuron gene 2 (SMN2), often known as the SMA backup gene, is a second gene that is present in all people with SMA in at least one and frequently numerous copies. Although SMN2 also creates SMN protein, the body can only utilize a limited portion of this protein. Numerous therapies that increase the usability of SMN protein target the SMN2 gene. Other SMN-enhancing methods directly replace or correct the mutated SMN1 gene.
Considering motor neurons are the cells most severely impacted by SMA, neuroprotective measures directed at this group of neurons may be successful, especially when combined with SMN-restoring therapy. One of the main symptoms of SMA type 2/3 is repeated nerve conduction and increased fatigability investigations reveal a decline, indicating that neuromuscular junction (NMJ) dysfunction may be significantly contributing to fatigability.
Therefore, pyridostigmine, an acetylcholinesterase inhibitor commonly recommended for myasthenia gravis, is presently being studied in phase II clinical trials to determine its impact on the efficiency of cholinergic transmission. According to early observations, pyridostigmine decreases patient fatigability and therefore, is considered a potential supplementary therapy.
Several studies were conducted in this region to figure out the psychosocial impacts of SMA on patients, families, and caretakers. More than half of the participants reported experiencing stress, and the majority of the caregivers reported experiencing anxiety. This is consistent with earlier studies that reported the great emotional costs associated with living with SMA. This may be because getting psychological counseling is culturally stigmatized in Asia, where people are taught to keep their emotions to themselves.
The China market dominated the Asia Pacific Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $523.6 million by 2028. The Japan market is estimated to grow a CAGR of 18.6% during (2022-2028). Additionally, The India market would experience a CAGR of 20.1% during (2022-2028).
Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Australia, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
Survival motor neuron gene 2 (SMN2), often known as the SMA backup gene, is a second gene that is present in all people with SMA in at least one and frequently numerous copies. Although SMN2 also creates SMN protein, the body can only utilize a limited portion of this protein. Numerous therapies that increase the usability of SMN protein target the SMN2 gene. Other SMN-enhancing methods directly replace or correct the mutated SMN1 gene.
Considering motor neurons are the cells most severely impacted by SMA, neuroprotective measures directed at this group of neurons may be successful, especially when combined with SMN-restoring therapy. One of the main symptoms of SMA type 2/3 is repeated nerve conduction and increased fatigability investigations reveal a decline, indicating that neuromuscular junction (NMJ) dysfunction may be significantly contributing to fatigability.
Therefore, pyridostigmine, an acetylcholinesterase inhibitor commonly recommended for myasthenia gravis, is presently being studied in phase II clinical trials to determine its impact on the efficiency of cholinergic transmission. According to early observations, pyridostigmine decreases patient fatigability and therefore, is considered a potential supplementary therapy.
Several studies were conducted in this region to figure out the psychosocial impacts of SMA on patients, families, and caretakers. More than half of the participants reported experiencing stress, and the majority of the caregivers reported experiencing anxiety. This is consistent with earlier studies that reported the great emotional costs associated with living with SMA. This may be because getting psychological counseling is culturally stigmatized in Asia, where people are taught to keep their emotions to themselves.
The China market dominated the Asia Pacific Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $523.6 million by 2028. The Japan market is estimated to grow a CAGR of 18.6% during (2022-2028). Additionally, The India market would experience a CAGR of 20.1% during (2022-2028).
Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Australia, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
Scope of the Study
By Type
- Type 1
- Type 2
- Type 3
- Type 4
By Route of Administration
- Injection
- Oral
By Treatment Type
- Drug
- Spinraza
- Zolgensma (AVXS-101)
- Evrysdi
- Others
- Gene Therapy
By Country
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Biogen, Inc.
- Novartis AG
- Ionis Pharmaceuticals, Inc.
- PTC Therapeutics, Inc.
- NMD Pharma A/S
- Scholar Rock, Inc. (Scholar Rock Holding Corporation)
- Cytokinetics, Inc.
- Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
- Astellas Pharma, Inc.
- F.Hoffmann-La Roche Ltd. (Genentech, Inc.)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific Spinal Muscular Atrophy Treatment Market by Type
Chapter 5. Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration
Chapter 6. Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type
Chapter 7. Asia Pacific Spinal Muscular Atrophy Treatment Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Biogen, Inc.
- Novartis AG
- Ionis Pharmaceuticals, Inc.
- PTC Therapeutics, Inc.
- NMD Pharma A/S
- Scholar Rock, Inc. (Scholar Rock Holding Corporation)
- Cytokinetics, Inc.
- Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
- Astellas Pharma, Inc.
- F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
Methodology
LOADING...
